Introduction
When I was invited to write this article my initial reaction was to question the need for another review on cardiovascular disease in women. As the medical profession has gradually recognised the fact that women develop cardiovascular disease, we have seen a progressive number of published articles in the field. Cardiologists, in particular, are considerably more aware of the size and importance of the problem. Many landmark studies have been undertaken and significant contributions to the subject have been made. Large sections of cardiological conferences are devoted to the subject of heart disease in women and several specialist journals have been spawned.
I believe that there is a need for the field to retain its current prominence for several reasons. Despite the fact that cardiologists are more aware of the problem, my personal experience is that this awareness has not spread to the same extent to other physicians, specialist or generalist. Perhaps more important, the general public is quite unaware that cardiovascular disease remains one of the biggest killers of women in developed countries. Although we have the benefit of many well conducted trials in the management of cardiovascular disease, albeit predominantly in white middle-aged men, together with a strong emphasis on evidence-based practice, the ASPIRE study 1 proved to us all that risk factor modification is generally poorly done, despite the profession's best intentions. Add to that a woman's ignorance of her own cardiovascular risk status, and the size of the problem becomes apparent.
One of the main reasons for the ignorance surrounding heart disease in women lies in the age difference at onset of heart disease in men and women. Compared with men, there is a 7 to 10 year delay in the symptomatic onset in women. 2 Previously this statistic was obscured by the generally shorter life expectancies of both men and women. The increasing longevity of developed societies will serve to emphasise not only the later presentation of heart disease in women but also the increasing numbers of women living several decades of their lives in the postmenopausal state, at a time of ever increasing cardiovascular risk.
The size of the problem

The public's perception
Although coronary heart disease is an uncommon cause of death in younger women, after the age of 60 years it becomes the primary cause of death, similar to men. 3 For a 50-year-old woman, her lifetime risk of having coronary heart disease is 46% and the risk of dying from it is 31%. 4 In contrast, her lifetime risk of having breast cancer is 10%, with only a 3% risk of dying from it. In the US each year, more than 236 000 women die from myocardial infarction and more than 87 000 women die from stroke. However, possibly because of the similar incidence of breast cancer and heart disease in younger women 5 ( Figure  1 ), the public's perception is that breast cancer poses the greater threat. Pilote and Hlatky 6 elegantly demonstrated this fact in a survey of 600 female Stanford University graduates (1967) (1968) (1969) (1970) (1971) , interviewed in 1993. The group as a whole was highly educated (66% had masters degrees, 22% doctoral degrees). Three-quarters of the respondents perceived their risk of developing heart disease by the age of 70 years to be less than 1%. In contrast, 52% believed that their risk of developing breast cancer to be 10% or greater.
The statistical reality
In Britain, although the risk of dying from coronary heart disease up to age 65 years is 3.5 greater in men than in women, the risk is similar after age 65 years. 7 Despite a variable fall in coronary heart disease mortality in most developed countries, the absolute number of coronary heart disease deaths in older age groups (eg, 75+ years) has increased dramatically. 8 This has been seen in both men and women and is due to the increase in life expectancy, associated with improvements in medical and social provision. Population demographics are changing so rapidly that it has been predicted that China, for example, will double its population of individuals aged more than 65 years in 27 years. Corresponding figures for Australia, the UK and the US are 28 years, 45 years and 80 years, respectively. 8 The number of people aged 85+ years in the US was 1 million in 1970, is currently 3.3 million and will rise in 30 years to between 16 and 23 million. This is an age group with a 10% prevalence of heart failure and a 30% prevalence of coronary heart disease. Because of the large population of older women, in 1990 cardiovascular disease caused more deaths in women than in men (46% of all deaths vs 40%).
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The double edged sword of longevity for women Whereas women may once have boasted their greater life expectancy over men, there is dawning a gradual realisation that there are significant downsides to longevity. Putting aside the immense economic problems associated with an aging population, there are additional problems, specific to women. There is an almost complete absence of data on the value of cardiovascular treatments and interventions in older women. For seemingly sensible reasons at the time, most cardiovascular trials have been conducted in middle-aged men. We shall be faced with an elderly female population in whom the increasingly popular practice of evidence-based medicine will simply not be possible.
As significant numbers of women live well into their 70s, 80s and 90s, so will they spend an increasing proportion of their life in the postmenopausal state. It is now well established that the oestrogen status of a woman is an important cardiovascular risk factor. 2 Since the average age of menopause is 52 years in the UK, it is not uncommon for women to spend 20, 30 or more years in the postmenopausal state. At last we have trials in progress on the value of hormone replacement therapy (HRT) in primary and secondary prevention, the results of which we await eagerly.
The typical female cardiovascular risk factor profile
Epidemiological surveys, such as Framingham, permit useful comparisons between men and women with regard to cardiovascular risk. For example, the Framingham report illustrates the different presentations (angina, myocardial infarct, unstable angina and sudden death) and risk factor profiles in men and women. Women are more likely to present with angina (47%) whereas men are more likely to present with myocardial infarction (46%). 10 Women with angina are older than men (64 years vs 61 years) and tend to have worse risk factor profiles, with higher cholesterol levels (6.71 vs 6.19 mmol/l), more diabetes mellitus (12% vs 10%) and hypertension (49% vs 35%). In contrast, compared with men the prognosis is better for women presenting with angina, but is similar or worse for women presenting with myocardial infarction. This apparent discrepancy is partly explained by a greater proportion of women than men being misclassified as having angina, rather than non-cardiac pain.
The Renfrew and Paisley study of 15 399 adults, aged 45-64 years when screened between 1972 and 1976, reported a 15-year follow-up in 1992.
11 Plasma cholesterol, smoking, diastolic blood pressure and low social class were positively and independently associated with coronary heart disease mortality in both sexes. The relative risk of coronary death was similar for each risk factor for men and women but the absolute risks were lower for women, such that, for a given risk factor, women with high risks tended to have a lower coronary mortality than men with low risks (Table 1) . Ironically, more lives could theoretically have been saved if the whole population had not smoked than by any other single intervention (assuming that these other measures would completely reverse risk). Given that in Europe more young women than young men smoke, the message is clear.
Other than 'risk' factors exclusive to women found that classical risk factors scored more strongly in both sexes for predicting cardiovascular risk than new ones. Relative risk was often higher for women but levels of absolute risk were frequently lower. For all coronary heart disease the same eight factors appeared in the top 12 for both sexes, for coronary heart disease death the same nine, and for all deaths the same 10. Total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure and previous angina all ranked within the top six risk factors for coronary disease events in men and women; diabetes ranked 7th in women and 21st in men, in keeping with other studies showing a greater cardiovascular risk from diabetes in women.
The lipid profile
The lipid profile changes during life, becoming more atherogenic after the menopause. 13 LDL cholesterol levels are lower in premenopausal women than in men, rising to higher levels than in men after the menopause. Triglyceride levels and lipoprotein(a) also rise after the menopause; HDL cholesterol levels fall. Most of the studies on cholesterol and heart disease have been in middle-aged men and a strong positive relationship has been found. The evidence is less strong for women and the absolute risk for a given cholesterol level is considerably lower. 11 All the same, most prospective studies have demonstrated a positive relationship between total cholesterol and coronary heart disease in women. 14 Compared with LDL cholesterol, HDL cholesterol is a strong (negative) predictor of coronary heart disease in women 15 and, in the Lipid Research Clinics Follow-up Study, was second only to age as a predictor of cardiovascular death. 16 The ratio of total to HDL cholesterol is a more reliable discriminator than total cholesterol alone of the presence of coronary artery disease in women. 17 The Framingham data indicate that a ratio greater than 5.0 identifies a person at high risk; 18 when the ratio exceeds 7.5 the risk is the same as for men. Whereas most studies have not shown triglycerides to be an independent risk factor for coronary heart disease in men, the evidence in women is more consistent. 15, 19 Lipoprotein(a) has recently been shown to be a determinant of coronary heart disease in both preand postmenopausal women. 20 Trials of lipid lowering have been conducted predominantly in men and less is known about the effects in women. To date there is no evidence that primary prevention reduces total mortality in women and we must await the results of ongoing studies. There is evidence, however, that women benefit from secondary prevention. The more recent trials of statins in secondary prevention, such as 4S 21 and CARE, 22 indicate that women benefit similarly to men from lipid lowering. Indeed, pravastatin lowered the rate of coronary events more among women than among men. 22 In summary, the lipid profile of women is different to that in men and it changes with age and hormonal status. The individual components should be measured since their predictive value is different in women. Generally, women tolerate high cholesterol levels better than do men. Information on primary prevention in women is lacking and on secondary prevention is limited.
Hypertension
Affecting more than a quarter of the industrialised world, hypertension is a major risk factor for stroke, heart failure and ischaemic heart disease, three of the most important causes of morbidity and mortality. 23 Equally, hypertension is potentially one of the most modifiable risk factors. The prevalence of hypertension is higher in men than in women until age 60 years. In white subjects older than 70 years, and in black and Hispanic subjects older than 60 years, the age-specific hypertension rate is higher in women than in men. Overall the percentages of men and women with hypertension (controlled and uncontrolled) range from 26 to 48% in black women, 21 to 30% in white women, 22 to 50% in black men and 20 to 30% in white men in population-based surveys. 24, 25 Left ventricular hypertrophy, a consequence of uncontrolled hypertension, is associated with greater cardiovascular risk in women than in men, 26 removing the female advantage with respect to cardiovascular risk. Hypertension is a more frequent cause of stroke in women (59% vs 39% in men) and is a greater risk factor for the development of congestive heart failure. 27 Women are more likely to have salt-sensitive hypertension if they have a family history of hypertension, 28 suggesting that thiazide diuretics should be the agent of first choice.
Guidelines for the treatment of hypertension do not discriminate between the sexes and yet, based on the evidence from clinical trials, the effects and potential benefits of treatment differ significantly between the sexes and according to age. Overall, men of all ages and elderly women benefit from antihypertensive therapy. Data on younger women are less clear. Moreover, of the relatively small number of trials on which treatment guidelines are based, several did not include women. [29] [30] [31] Somewhat discordant results have been found in the early trials including women (Table 2) . 32 For example, the MRC trial of mild hypertension 33 was associated with a 15% reduction in mortality in men and an unexpected 26% increase in mortality amongst women. Interestingly, the earlier HDFP trial 34 reported a decrease in mortality in black women and all men but there was a small (2.5%) but insignificant increase in mortality in white women. In addition the increase in mortality in white women was greater the higher the diastolic blood pressure. However, the results should be interpreted cautiously because of the limitations of subgroup analysis and small numbers. In support of this, the HDFP posttrial follow-up showed a significant mortality advantage in both black and white women. 35 Recent trials have produced more consistent results. In the European study of hypertensive patients aged Ͼ60 years 38 cardiovascular mortality was reduced in both men and women, although the benefit was considerably greater in men (47% reduction vs 18%). Significant cardiovascular benefit was also found in the Swedish Trial in Old Patients (STOP-Hypertension) 39 and in the Systolic Hypertension in the Elderly Program (SHEP). 40 In SHEP, treatment of isolated systolic hypertension in patients aged over 60 years was associated with significant reductions in the incidence of stroke (36%), myocardial infarction (27%) and all cardiovascular events (32%), and there were no significant gender differences. Most recently TOMHS, the Treatment of Mild Hypertension Study, reported similar treatment benefits in men and women. 41 In summary, hypertension is more common in women than men and is an important cause of cardiovascular morbidity and mortality. Although data are limited and somewhat conflicting, most women, particularly blacks, the elderly and those with systolic hypertension, will benefit from antihypertensive therapy.
Hormonal status
The oestrogen status of a woman is a highly important factor with regard to coronary heart disease risk. It is well-established that the incidence of coronary artery disease rises after the menopause, whether natural or surgically induced. As far back as the 1950s it was recognised that women who had had both ovaries removed had an increased incidence of coronary artery disease. 42 How much the increased cardiovascular risk with a natural menopause is due to oestrogen deficiency and how much to the effects of aging is uncertain, since the two are inextricably linked. However, there is considerable evidence that oestrogen replacement has important cardiovascular benefits. Over the years many studies (observational, case-controlled and cohort) have reported on the effects of oestrogen replacement therapy (HRT) and, despite the recognised limitations of many of the studies, the majority have reported a significant cardioprotective effect from HRT, estimated to be a risk reduction of 44% in one meta-analysis. 43 Despite these findings, the medical world has been slow to embrace the concept of oestrogen replacement as a potent cardioprotective agent, for several reasons. In the early 1970s oestrogens were found to increase the risk of coronary heart disease in men. 44 The older formulations of oral contraceptives, for so long incorrectly compared with HRT, increased cardiovascular risk in middle-aged women. 45 Coupled with evidence for an increased risk of endometrial cancer if oestrogen replacement was given unopposed (ie, without a progestin), 46 it is not surprising that oestrogen replacement was not considered as a useful cardioprotective agent in oestrogen-deficient women until quite recently.
There are considerable data from in vitro and animal work to show that oestrogens have beneficial effects on the cardiovascular system. A significant part of the cardioprotection afforded by oestrogen is thought to be due to the beneficial effects on the lipid profile, which fortunately is not much attenuated by concomitant progestin therapy. 47 Oestrogens have many other potentially beneficial effects including vasodilatation 48 and an antioxidant action, 49 to name but two. Now that interest has been rekindled in the role of oestrogen replacement in coronary heart disease, trials are in progress to assess the role of currently prescribed hormone replacement formulations in the primary and secondary prevention of heart disease in women. The Heart and Estrogen/Progestin Replacement Study (HERS) in the US is a secondary prevention trial expected to report very soon. The Women's Health Initiative (WHI), also from the US, includes women with and without heart disease, and will address the breast cancer issue associated with longer term oestrogen replacement. The study is not expected to report for at least 10-12 years.
In the meantime we must be guided by the data available and adopt a practical stance. HRT should be offered to postmenopausal women with established coronary artery disease and to those at high risk of developing it. Women with a history of cancer or a family history of breast cancer should not be offered HRT. Combined therapy (oestrogen and a progestin) is necessary to minimise the risk of endometrial carcinoma. A common misconception is that HRT should not be given to women with diabetes or hypertension. Finally, HRT has considerable other benefits, not least in the management of menopausal symptoms (!), but also for osteoporosis prevention and possibly in the genesis of colorectal carcinoma and Alzheimer's disease. 50 
Smoking
Cigarette smoking is the leading preventable cause of death in men and women in the United States. There is strong evidence that the risk of coronary artery disease is up to four times higher in women who smoke heavily compared with women nonsmokers. 51 Furthermore, there is no safe level of smoking -even light smokers (1-4 cigarettes/day) have more than double the risk of coronary artery disease (Table 3) . 52 Ex-smokers have a risk only slightly higher than non-smokers. The effect of smoking in combination with another cardiovascular risk factor was recently highlighted in the Nurses Health study. 52 For example, the relative risk for coronary heart disease was 22.2 for a hypertensive smoker compared with a normotensive non-smoker, 18.9 for a hypercholesterolaemic smoker compared with a normocholesterolaemic non-smoker and 22.3 for a diabetic smoker compared with a non-diabetic non-smoker.
In an interesting study by Rosenberg et al, 53 assessing the smoking habits of women suffering their first myocardial infarction, the relative risk of a first myocardial infarction in current smokers compared with non-smokers was 3.6, falling rapidly in exsmokers to match non-smokers' risks within 3 years. The pattern of decline was independent of the number of cigarettes smoked and the duration of smoking. The risks of smoking appear to be greater in women, who have a relative risk of myocardial infarction 50% greater than do men. 54 The cause of the sex difference is unknown but there is growing evidence that women smokers are relatively oestrogen-deficient compared with non-smoking women. A recent OCPS survey showed that more young females smoke compared with men, 55 a finding that has been replicated in other surveys. At the present time, due to changes in the smoking habit 
Diabetes mellitus and insulin resistance
Diabetes mellitus is one of the strongest risk factors for coronary heart disease in women, neutralising the female advantage. Mortality rates from coronary artery disease are between three and seven times higher in diabetic women compared with non-diabetic women, in contrast to the two-to four-fold increase in diabetic vs non-diabetic men. 56, 57 Diabetics are more frequently hypertensive, obese and have less favourable lipid profiles, possibly all linked to underlying insulin resistance. Cigarette smoking, hypertension and obesity act synergistically with diabetes, 58 such that the benefits from aggressive control of these risk factors is greater than in the non-diabetic population.
Additional risk factors
Other factors that have been associated with coronary risk in women include obesity and a waist:hip ratio of Ͼ0.8. 59 Obesity may not be an independent risk factor per se since it is associated with other risk factors such as hypertension, diabetes mellitus and hyperlipidaemia. The beneficial effects of exercise are not obviously linked to a reduction in cardiovascular diease. 60 Low birth weight is associated with an increased cardiovascular mortality in later life in both men and women. 61 Mild-to-moderate alcohol intake is associated with lower levels of cardiovascular risk, perhaps partly due to the apparent U-shaped relationship between alcohol consumption and plasma concentrations of triglycerides and insulin. 62 In a study of over 34 000 postmenopausal women, the intake of vitamin E from food was inversely associated with the risk of death from coronary heart disease, although there was little evidence for additional benefit from vitamin E supplements. 63 There was no association between vitamin A and C intake and coronary heart disease mortality.
Conclusion
Coronary heart disease remains a major cause of morbidity and mortality in women. There are important gender differences, not only with respect to cardiovascular risk factors, but also in the presentation, management and prognosis of heart disease in women. The medical profession is gradually realising the magnitude of the problem but it will need continuing efforts before the general public begins to recognise heart disease as more than a man's disease. Only then will we see important changes in the primary and secondary prevention of heart disease, particularly with respect to cigarette smoking and the role of hormone replacement therapy. It is really quite incredible that the HRT issue is still unresolved after more than a quarter of a century of study.
